Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility – Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women’s Health) pipeline landscape.
Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility.
Click here to Get free PDF Sample : http://www.marketresearchglobe.com/request-sample/241534
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Women Infertility – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.
Women Infertility (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Complete Browse Report@ http://www.marketresearchglobe.com/report/women-infertility-pipeline-review-h1-2017
– The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women’s Health).
– The pipeline guide reviews pipeline therapeutics for Women Infertility (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Women Infertility (Women’s Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Women Infertility (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women’s Health)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Women Infertility (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content:
acolbifene hydrochloride + GnRH Agonist + prasterone – Drug Profile 52
ADX-68692 – Drug Profile 53
AKP-501 – Drug Profile 54
ASP-1707 – Drug Profile 55
barusiban – Drug Profile 56
BAY-1128688 – Drug Profile 57
BAY-1158061 – Drug Profile 58
Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis – Drug Profile 59
Biosimilar 5 for Infertility and Oncology – Drug Profile 60
Biosimilar 6 for Infertility, Oncology and Immunology – Drug Profile 61
Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology – Drug Profile 62
choriogonadotropin alfa biosimilar – Drug Profile 63
choriogonadotropin alfa biosimilar – Drug Profile 64
danazol – Drug Profile 65
Drug 1 for Endometriosis – Drug Profile 66
Drug 2 for Endometriosis – Drug Profile 67
Drug 3 for Endometriosis – Drug Profile 68
Drug 4 for Endometriosis – Drug Profile 69
Drug 5 for Endometriosis – Drug Profile 70
Drug to Antagonize P2X3 for Endometriosis – Drug Profile 71
Drug to Inhibit C-Jun for Endometriosis – Drug Profile 72
Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women’s Health – Drug Profile 73
Drugs for Endometriosis and Uterine Fibroids – Drug Profile 74
EC-313 – Drug Profile 75
elagolix sodium – Drug Profile 76
EVE-104 – Drug Profile 81
FE-999310 – Drug Profile 82
fezolinetant – Drug Profile 83
follicle stimulating hormone biosimilar – Drug Profile 86
follitropin alfa biosimilar – Drug Profile 87
follitropin alfa biosimilar – Drug Profile 89
follitropin alfa biosimilar – Drug Profile 90
follitropin delta – Drug Profile 91
FP-5677 – Drug Profile 93
FSH-GEX – Drug Profile 94
goserelin biosimilar – Drug Profile 96
goserelin ER – Drug Profile 97
Isifera – Drug Profile 98
kisspeptin-54 – Drug Profile 99
Follow Us :
Twitter : https://twitter.com/marketrglobe